Discover
Zejula (niraparib) / GSK, ZAI Lab, J&J, TakedaZai Lab announces China’s NMPA grants Priority Review to the sNDA for Zejula (niraparib) for first-line ovarian cancer maintenance treatment (GlobeNewswire) - Apr 16, 2020 - "Zai Lab Limited...announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted priority review status to the supplemental New Drug Application (sNDA) for ZEJULA (niraparib) as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy."
AsiDNA (etidaligide) / Onxeo; Zejula (niraparib) / GSK, ZAI Lab, J&J, TakedaOnxeo reports full-year 2019 financial results and provides business update (GlobeNewswire) - Apr 17, 2020 - "The study, sponsored by Gustave Roussy, will evaluate the effect of AsiDNA™ on the acquired resistance to PARP inhibitor niraparib in 2nd line maintenance treatment of relapsed ovarian is currently under review by the French agency (ANSM) and Ethics Committee. Assuming the recruitment can start from mid-year, the Company aims to obtain preliminary results by year-end 2020 or early in 2021....Proof-of-concept preclinical studies of OX401 are ongoing with results expected this year."
